Allogeneic Placental-Derived Product Candidates
Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic products for indications where the demonstrated properties of such cells could provide an advantage, both in terms of development (sourcing and proliferation) and potential efficacy (affinity). In selecting indications, we evaluate where the biological properties of the placenta positions our products for success, and where there is a clearly defined regulatory pathway that provides the potential for accelerated development to address unmet patient need.
CLINICAL PIPELINE
Hematological Malignancies | Platform | Functionality | Indication | Discovery | IND-Enabling | Phase 1/2 | Phase 2/3 |
CYNK-001 | pNK | Unmodified | AML | ![]() |
|||
CYNK-301 | pNK | IL15 + Marrow Homing + CAR | AML | ![]() |
|||
CYCART-19 | pT | CD19 + TCR KO | NHL, MCL | ![]() |
|||
CYCART-201 | pT | CD16 + TCR KO + mAb | NHL, MCL | ![]() |
|||
Solid Tumor | Platform | Functionality | Indication | Discovery | IND-Enabling | Phase 1/2 | Phase 2/3 |
CYCART-201 | pT | CD16 + TCR KO + mAb | HER2+ Tumors | ![]() |
|||
CYNK-302 | pNK | CD16 + IL15 + CAR | NSCLC | ![]() |
|||
Autoimmune & Degenerative Disease | Platform | Functionality | Indication | Discovery | IND-Enabling | Phase 1/2 | Phase 2/3 |
APPL-001 | MLASC | TF KO | Crohn’s Other potential indications |
![]() |
|||
pEXO-001 | pEXO | Unmodified | Osteoarthritis | ![]() |
BIOMATERIAL PIPELINE
Degenerative Diseases | Indication | Discovery | Regulatory | Brands | |
Placental Connective Tissue Matrix | Integumental Tissue Replacement | ![]() |
|||
Amniotic Membrane Allograft | Wound Covering | ![]() |
|||
Tri-Layer Amniotic Membrane Allograft | Wound Covering | ![]() |
|||
Tri-Layer Amniotic Membrane Allograft | Protective Cover | ![]() |
|||
Connective Tissue Wrap | Tendon | ![]() |
|||
Placental Extracellular Matrix Osteoconductive Properties | Bone, Spine, Dental | ![]() |
|||
Degenerative Diseases | Indication | Discovery | Regulatory | Regulatory | Brands |
Extracellular Matrix Particulates | Aesthetics | ![]() |
|||
Extracellular Matrix Particulates | Osteoarthritis | ![]() |
CLINICAL PIPELINE
Hematological Malignancies | Platform | Functionality | Indication |
CYNK-001 | pNK | Unmodified | AML |
Discovery | IND-Enabling | Phase 1/2 | Phase 2/3 |
![]() |
Hematological Malignancies | Platform | Functionality | Indication |
CYNK-301 | pNK | IL15 + Marrow Homing + CAR | AML |
Discovery | IND-Enabling | Phase 1/2 | Phase 2/3 |
![]() |
Hematological Malignancies | Platform | Functionality | Indication |
CYCART-201 | pT | CD19 + TCR KO | NHL, MCL |
Discovery | IND-Enabling | Phase 1/2 | Phase 2/3 |
![]() |
Hematological Malignancies | Platform | Functionality | Indication |
CYCART-201 | pT | CD16 + TCR KO + mAb | NHL,MCL |
Discovery | IND-Enabling | Phase 1/2 | Phase 2/3 |
![]() |
Solid Tumor | Platform | Functionality | Indication |
CYCART-201 | pT | CD16 + TCR KO + mAb | HER2+ Tumors |
Discovery | IND-Enabling | Phase 1/2 | Phase 2/3 |
![]() |
Solid Tumor | Platform | Functionality | Indication |
CYNK-302 | pNK | CD16 + IL15 + CAR | NSCLC |
Discovery | IND-Enabling | Phase 1/2 | Phase 2/3 |
![]() |
Autoimmune & Degenerative Disease | Platform | Functionality | Indication |
APPL-001 | MLASC | TF KO | Crohn's Other potential indications |
Discovery | IND-Enabling | Phase 1/2 | Phase 2/3 |
![]() |
Autoimmune & Degenerative Disease | Platform | Functionality | Indication |
pEXO-001 | pEXO | Unmodified | Osteoarthritis |
Discovery | IND-Enabling | Phase 1/2 | Phase 2/3 |
![]() |
BIOMATERIAL PIPELINE
Degenerative Disease | Indication | ||
Placental Connective Tissue Matrix | Integumental Tissue Replacement | ||
Preclinical | Regulatory | Phase 2 | |
![]() |
Degenerative Disease | Indication | ||
Amniotic Membrane Allograft | Wound Covering | ||
Preclinical | Regulatory | Phase 2 | |
![]() |
Degenerative Disease | Indication | ||
Tri-Layer Amniotic Membrane Allograft | Wound Covering | ||
Preclinical | Regulatory | Phase 2 | |
![]() |
Degenerative Disease | Indication | ||
Tri-Layer Amniotic Membrane Allograft | Protective Cover | ||
Preclinical | Regulatory | Phase 2 | |
![]() |
Degenerative Disease | Indication | ||
Connective Tissue Wrap | Tendon | ||
Preclinical | Regulatory | Phase 2 | |
![]() |
Degenerative Disease | Indication | ||
Placental Extracellular Matrix Osteoconductive Properties | Bone, Spine, Dental | ||
Preclinical | Regulatory | Phase 2 | |
![]() |
Degenerative Disease | Indication | ||
Extracellular Matrix Particulates | Aesthetics | ||
Preclinical | Regulatory | Phase 1 | Phase 2 |
![]() |
Degenerative Disease | Indication | ||
Extracellular Matrix Particulates | Osteoarthritis | ||
Preclinical | Regulatory | Phase 1 | Phase 2 |
![]() |
Developing Therapies for a Range of Diseases
Celularity is investigating allogeneic therapies that are ready-to-use and eliminate the need for matching patients with donors.
We believe we are only in the early stages of unlocking the full potential of the Celularity IMPACT platform (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).